市場調査レポート
商品コード
1492503
細胞凍結培地市場:タイプ、用途、最終用途別-2024-2030年の世界予測Cell Freezing Media Market by Type (Dimethyl Sulfoxide-based Media, Glycerol-Based Media, Serum-Free Media), Application (Biobanking, Cancer Research, Genetic Engineering & CRISPR Technology), End-Use - Global Forecast 2024-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
細胞凍結培地市場:タイプ、用途、最終用途別-2024-2030年の世界予測 |
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
|
細胞凍結培地市場規模は、2023年に1億8,571万米ドルと推定され、2024年には2億166万米ドルに達し、CAGR 8.71%で2030年には3億3,325万米ドルに達すると予測されています。
細胞凍結培地は、細胞を極低温で保存するための特殊なソリューションです。ジメチルスルホキシド(DMSO)やグリセロールなどの凍結保護剤をバランスよく混合したもので、凍結中の氷結晶形成から細胞を保護します。これらの凍結保護剤は、細胞の損傷を最小限に抑え、解凍時に細胞の生存率と機能性を維持する上で極めて重要です。先端バイオ医薬品に対する需要の急増と細胞治療分野の成長は、細胞凍結培地市場の好況にさらに貢献しています。これらの治療法は細胞の保存に大きく依存しており、効果的な凍結培地の役割は不可欠です。しかし、高度な保存技術には高いコストがかかり、細胞の取り扱いと保存に関する厳しい規制要件が、製造業者や供給業者に大きな課題を突きつけています。企業はコスト削減と規制遵守に努め、この環境下で機敏な対応を続けています。拡大機会は、カスタマイズされた凍結ソリューションの開発、新興国市場での成長、凍結保存の成果を向上させるためのAIやIoTなどの最先端技術の統合にあると見られています。
主な市場の統計 | |
---|---|
基準年[2023] | 1億8,571万米ドル |
予測年[2024] | 2億166万米ドル |
予測年 [2030] | 3億3,325万米ドル |
CAGR(%) | 8.71% |
地域別インサイト
米国、カナダは、堅調なバイオテクノロジーセクター、充実した研究開発投資、大手製薬会社の存在により、細胞凍結培地市場の最前線に立っています。凍結保存技術や製剤に関する技術革新や特許が頻繁に報告されており、先進的な細胞凍結ソリューションに対する需要が高いことを示しています。細胞治療と再生医療の採用が、この地域の市場成長をさらに後押ししています。EMEAの細胞凍結培地市場は先進的であり、品質、革新性、厳格な規制基準の遵守を強く重視しています。この地域は幹細胞研究、個別化医療、バイオバンクに重点を置いており、洗練された細胞凍結ソリューションに対する安定した需要に貢献しています。研究協力やEUの資金提供によるイニシアチブは、市場力学において重要な役割を果たしています。中東・アフリカ地域は、研究活動への投資の増加とともに市場が緩やかに成長しており、細胞ベースの治療に対する意識の高まりが市場の進化に寄与しています。さらに、アジア太平洋地域は、バイオテクノロジーの著しい進歩や細胞長期保存のための凍結保存法への傾倒の高まりにより、細胞凍結培地市場の堅調な拡大を経験しています。研究開発活動、バイオバンクの増加、中国、日本、インドなどの国々における再生医療需要の急増がこの成長をさらに後押ししています。さらに、ヘルスケア・インフラの強化を目的とした政府の取り組みや、製薬・バイオ医薬品部門への投資の増加が、市場のプラス成長に寄与しています。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは、細胞凍結培地市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を調査します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。
市場シェア分析
市場シェア分析は、細胞凍結培地市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。
戦略分析と推奨
戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、細胞凍結培地市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。
[187 Pages Report] The Cell Freezing Media Market size was estimated at USD 185.71 million in 2023 and expected to reach USD 201.66 million in 2024, at a CAGR 8.71% to reach USD 333.25 million by 2030.
Cell freezing media is a specialized solution to preserve cells in extremely low temperatures. It comprises a balanced mixture of cryoprotectants, such as dimethyl sulfoxide (DMSO) and glycerol, protecting the cells from ice crystal formation during freezing. These cryoprotectants are crucial in minimizing cellular damage and maintaining cell viability and functionality upon thawing. The surging demand for advanced biopharmaceuticals and the growing cell therapy sector further contribute to the positive trajectory of the cell freezing media market. These therapies rely extensively on the preservation of cells, making the role of effective freezing media indispensable. However, the high cost of advanced preservation technologies and stringent regulatory requirements for cell handling and storage pose significant challenges for manufacturers and suppliers. Companies frequently work towards cutting costs and adhering to regulations to remain agile within the landscape. Expansion opportunities are seen in developing customized freezing solutions, growth in emerging markets, and integrating cutting-edge technologies such as AI and IoT to refine cryopreservation outcomes.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 185.71 million |
Estimated Year [2024] | USD 201.66 million |
Forecast Year [2030] | USD 333.25 million |
CAGR (%) | 8.71% |
Regional Insights
In America, the United States, and Canada stand at the forefront of the cell-freezing media market, owing to its robust biotechnology sector, substantial research and development investments, and major pharmaceutical companies. Innovations and patents in cryopreservation techniques and formulations are frequently reported, demonstrating a high demand for advanced cell freezing solutions. Adopting cell therapy and regenerative medicine further propels market growth in the region. The EMEA market for cell freezing media is advanced, strongly emphasizing quality, innovation, and compliance with stringent regulatory standards. The region's focus on stem cell research, personalized medicine, and biobanking contribute to a steady demand for sophisticated cell freezing solutions. Research collaborations and EU-funded initiatives play a significant role in market dynamics. The Middle East and Africa region are experiencing gradual growth in the cell freezing media market with rising investment in research activities, and increasing awareness about cell-based therapies contributes to market evolution. Moreover, the Asia Pacific region is experiencing a robust expansion in the cell freezing media market, owing to significant advancements in biotechnology and an increasing inclination towards cryopreservation methods for long-term cell storage. A rise in research and development activities, biobanking, and a surge in demand for regenerative medicine across countries such as China, Japan, and India further fuels this growth. Additionally, government initiatives aimed at bolstering healthcare infrastructure, along with growing investments in the pharmaceutical and biopharmaceutical sectors, are contributing to the positive trajectory of the market.
Market Insights
The market dynamics represent an ever-changing landscape of the Cell Freezing Media Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cell Freezing Media Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cell Freezing Media Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Sartorius completes acquisition of Polyplus
Sartorius, an entity in the life sciences sector, completed the acquisition of Polyplus through its subsidiary, Sartorius Stedim Biotech. Polyplus specializes in developing and producing pivotal transfection reagents in viral vector manufacturing. This acquisition augments Sartorius's capabilities in this domain and signifies Polyplus's expansion into complementary technologies. By venturing into plasmid design and protein and plasmid production, Polyplus is diversifying its offerings and enhancing its technological portfolio to better serve the evolving needs of gene-modified cell and gene therapies. [Published On: 2023-07-18]
Qkine and Sartorius Partnership Delivers a Complete Workflow Solution for the Analysis of Advanced Cell Models
Qkine partnered with Sartorius to enrich stem cell and organoid research by integrating Qkine's expertise in creating bioactive growth factors and cytokines with Sartorius's advanced portfolio of cell analysis technologies. Sartorius, celebrated for accelerating life science research and pharmaceutical development, offers a broad spectrum of products, including reagents, assays, and pioneering technologies such as automated cell culture and live-cell imaging. This partnership is positioned to propel advancements in biologic discovery, streamline cell line development processes, and enhance the development of sophisticated cell models, thus delivering a holistic workflow solution to the scientific community. [Published On: 2023-07-06]
ExCell Bio Launches a New Factory in Uruguay
ExCell Biotechnology Co., Ltd. celebrated the opening of its new facility, ARTICA BIOTECH S.A. This significant milestone occurred within the Zonamerica Free Trade Zone on the northeastern outskirts of Montevideo, Uruguay. ExCell Bio has distinguished itself through its dedication to innovation in developing upstream tools for the biopharmaceutical industry. The inauguration of ARTICA BIOTECH S.A. marks the company's second establishment in Uruguay. ExCell Bio has achieved a significant position in China's market segment with its serum product line, underscoring its commitment to excellence and growing influence in the global marketplace. [Published On: 2023-05-04]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cell Freezing Media Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Cell Freezing Media Market, highlighting leading vendors and their innovative profiles. These include Abcam Limited, AMSBIO, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, BPS Bioscience, Inc., Capricorn Scientific, Carl Roth GmbH + Co. KG, Celprogen Corporation, Charles River Laboratories, Elabscience Bionovation Inc., ExCell Biotechnology Co., Ltd, Funakoshi Co., Ltd., HiMedia Laboratories, Merck KGaA, NIPPON Genetics EUROPE GmbH, PAN-Biotech GmbH, PromoCell GmbH, Qiagen NV, Sartorius AG, STEMCELL Technologies, Thermo Fisher Scientific Inc., and WELGENE Inc..
Market Segmentation & Coverage